Pfizer Inc. (PFE) shares edged up 1.5% to $26.07 in late-morning trading on Monday, pushing its market capitalization to roughly $149 billion. The modest uptick followed a first-quarter earnings report that surpassed analyst expectations, yet the stock remains under pressure from looming patent expirations on key drugs and a steep decline from its COVID-era peak.
Q1 Earnings Beat, But Challenges Persist
The pharmaceutical giant reported first-quarter revenue of $14.45 billion and adjusted earnings of $0.75 per share, both exceeding consensus estimates. The company reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion. However, net income declined year-over-year as sales of COVID-19 products continued to slide. Comirnaty, Pfizer's COVID vaccine, saw first-quarter sales plunge 59%, while Paxlovid tumbled 62%.
Patent Cliff Looms
Pfizer faces a significant patent cliff, with exclusivity losses on major drugs including blood thinner Eliquis (co-marketed with Bristol Myers Squibb) and cancer treatment Ibrance. A recent settlement on heart drug Vyndamax delays U.S. generic competition until June 2031, though legal disputes remain. CEO Albert Bourla highlighted that resolving the Vyndamax case and a favorable European court ruling on COVID vaccine contracts have improved growth prospects beyond 2028, projecting a five-year period of high single-digit revenue CAGR starting in 2029.
Obesity and Cancer Pipeline
The company's push into the obesity market, led by the $10 billion acquisition of Metsera, is a long-term play. Its GLP-1 candidate is not expected to launch before 2028, pending successful trials. Eli Lilly and Novo Nordisk currently dominate this space. Chief U.S. Commercial Officer Aamir Malik noted that Pfizer's sales force already reaches nearly 60% of physicians likely to prescribe obesity medications.
In oncology, the FDA recently cleared Veppanu, a PROTAC protein-degrader therapy for advanced breast cancer, developed with Arvinas. Commercialization will require a third-party partner.
Dividend Appeal
Pfizer's dividend remains a key attraction for yield-focused investors. The company declared a second-quarter dividend of $0.43 per share, payable June 12, marking the 350th consecutive quarterly payout. The annualized dividend of $1.72 yields approximately 6.6% based on Monday's share price.
Analyst Caution
Despite the positive earnings beat, analysts remain cautious. J.P. Morgan's Chris Schott emphasized the need for more clinical data and risk reduction. Citi's Geoff Meacham pointed to growth in new and acquired drugs as a buffer against COVID revenue declines. RBC Capital's Trung Huynh characterized Pfizer as a “catalyst story,” with upcoming milestones in oncology, Metsera trials, and Vyndamax cash flow more critical than quarterly results.
Pfizer's path to recovery hinges on successfully navigating the patent cliff from 2026 to 2028, with new drug launches and pipeline progress serving as potential offsets. The stock's high dividend yield offers a cushion, but uncertainty remains.
